- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma


New VP of oncology research at Lilly

Greg Plowman is to take the position of Lilly’s Vice President, Oncology Research, and Senior Vice President of ImClone Systems research.

In this newly-created role, Plowman will oversee the oncology research efforts of both Lilly and its subsidiary, ImClone.

He will report jointly to Jan Lundberg, Executive Vice President, Science and Technology, and Oresident, Lilly Research Laboratories (LRL), and Bernhard Ehmer, President of ImClone.

“Oncology represents a major area of unmet medical need and rapidly advancing science is driving us to discover new treatments with better efficacy to prolong the survival of the patients we serve,” said Lundberg.

“The introduction of a new oncology research leader across Lilly and ImClone will ensure the pursuit of the right mechanisms, therapeutic agents and tailoring strategies across our oncology business.”

Lilly acquired ImClone in 2008, an acquisition that broadened the Lilly Oncology portfolio. The company now has more than 30 molecules in its clinical-stage pipeline.

Plowman has 25 years of experience in cancer research, including leadership roles at four biotechs (Oncogen, Sugen, Exelixis and Genentech) that became part of three pharmaceutical companies (Bristol-Myers Squibb, Pharmacia and Roche).

- Advertisement -


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription